Learn More
Human TACI/TNFRSF13B Antibody, R&D Systems™

Description
Specifications
Specifications
| Antigen | TACI/TNFRSF13B/CVID |
| Applications | Western Blot, Immunohistochemistry, Blockade of Receptor-ligand Interaction |
| Classification | Polyclonal |
| Concentration | LYOPH |
| Conjugate | Unconjugated |
| Dilution | Western Blot 0.1 ug/mL, Immunohistochemistry 5-15 ug/mL, Blockade of Receptor-ligand Interaction |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative |
| Gene Accession No. | Q53F36 |
| Gene Alias | CD267, CD267 antigen, CVID, CVID2, FLJ39942, MGC133214, TACIMGC39952, TNFRSF13B, TNFRSF14B, Transmembrane activator and CAML interactor, tumor necrosis factor receptor 13B, tumor necrosis factor receptor superfamily member 13B, tumor necrosis factor receptor superfamily, member 13B |
| Gene Symbols | TNFRSF13B |
| Show More |
For Research Use Only
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.